CEBPA and acute myeloid leukemia: The UPR is activated in a significant subset of AML patients through calreticulin induction along the ATF6 pathway, ultimately inhibiting CEBPA translation contributing to the blockade of myeloid differentiation, and contributing to leukemogenesis [77].